What question did this study set out to answer?

This research aims to explore how aldosterone affects endothelial nitric oxide levels and contributes to pulmonary arterial hypertension.

July 12, 2012CirculationOpen Access

Aldosterone Inactivates the Endothelin-B Receptor via a Cysteinyl Thiol Redox Switch to Decrease Pulmonary Endothelial Nitric Oxide Levels and Modulate Pulmonary Arterial Hypertension

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial demonstrates aldosterone disrupts ET(B)-eNOS signaling in pulmonary arterial hypertension, suggesting therapeutic targets.

This research aims to explore how aldosterone affects endothelial nitric oxide levels and contributes to pulmonary arterial hypertension.
Utilized rats with PAH to analyze endothelin-1 and aldosterone levels alongside nitric oxide metabolites.
Conducted experiments in human pulmonary artery endothelial cells to assess the interaction between endothelin-1 and aldosterone synthase.
Applied mineralocorticoid receptor antagonism with spironolactone to evaluate its effect on reactive oxygen species and nitric oxide production.
In PAH rat models, elevated endothelin-1 correlated with increased plasma and lung aldosterone levels and decreased lung NO(·) metabolites.
In endothelial cells, aldosterone increased reactive oxygen species, decreasing nitric oxide production via oxidative modification of ET(B)-Cys405.
Spironolactone restored ET(B)-dependent NO(·) production and improved pulmonary hemodynamics in rat models of PAH.

Maron et al. (2012) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial demonstrates aldosterone disrupts ET(B)-eNOS signaling in pulmonary arterial hypertension, suggesting therapeutic targets.